However, continuous anti-angiogenesis therapy increases tumor hypoxia and leads to increased performance of HIF-1α, which in turn promotes the production of pro-angiogenesis genes and causes tumor resistance to anti-angiogenesis therapy 47. This evidence concerns the gene HIF1A and neoplasm.